Prempro news | Breaking Prempro news

Wyeth Reports Results for the 2004 Fourth Quarter and Full Year

... A direct-to-consumer advertising campaign was launched in 2004 featuring The national television campaign and print campaign educates women about the appropriate use of hormone therapy and encourages dialogue between women and their health care professionals about the treatment of menopausal symptoms.Also contributing to Wyeth's growth in 2004 was ZOSYN.

Zosyn remains the second largest selling and fastest growing broad-spectrum I.V.

antibiotic globally.

Net revenue increased 19% to $760 million for the year, reflecting growth in both the U.S.

and internationally.Building on the success of Zosyn, Wyeth submitted a global registration dossier for the investigational antibiotic TYGACIL (tigecycline) in the fourth quarter.

On January 28, 2005, Wyeth announced that the FDA granted priority review status to the Company's New Drug Application (NDA) for Tygacil.

A priority designation can be given to an NDA for a drug that, if approved, would be a significant improvement compared with existing treatments.Wyeth is seeking market approval for Tygacil as a single agent therapy to treat patients with complicated intra-abdominal infections (cIAI) and complicated skin and skin structure infections (cSSSI), caused by gram-negative and gram-positive pathogens, anaerobes, and both methicillin-susceptible and methicillin-resistant strains of Staphylococcus aureus (MSSA and MRSA).

Complicated infections and antibiotic resistance are serious concer...

Prempro

News

Advertisers:

Wyeth Reports Results for the 2004 Fourth Quarter and Full Year